0001192482-13-000238.txt : 20131219
0001192482-13-000238.hdr.sgml : 20131219
20131219124723
ACCESSION NUMBER: 0001192482-13-000238
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131217
FILED AS OF DATE: 20131219
DATE AS OF CHANGE: 20131219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001361248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-889-9900
MAIL ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reed Douglas MD
CENTRAL INDEX KEY: 0001291262
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131287713
MAIL ADDRESS:
STREET 1: C/O VECTOR FUND MANAGEMENT
STREET 2: 1751 LAKE COOK ROAD, SUITE 350
CITY: DEERFIELD
STATE: IL
ZIP: 60015
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-12-17
0001361248
TETRALOGIC PHARMACEUTICALS CORP
TLOG
0001291262
Reed Douglas MD
C/O TETRALOGIC PHARMACEUTICALS CORP
343 PHOENIXVILLE PIKE
MALVERN
PA
19355
1
0
0
0
Common Stock
2013-12-17
4
P
0
142857
7.00
A
142857
I
See footnote
Common Stock
2013-12-17
4
C
0
780980
A
923837
I
See footnote
Common Stock
2013-12-17
4
C
0
278315
7.00
A
1202152
I
See footnote
Common Stock
2013-12-17
4
X
0
7590
6.4022
A
1209742
I
See footnote
Series C Convertible Stock
2013-12-17
4
C
0
780980
D
Common Stock
780980
0
I
See footnotes
Convertible Notes
7.00
2013-12-17
4
C
0
278315
D
Common Stock
278315
0
I
See footnotes
Warrants
6.4022
2013-12-17
4
X
0
7590
D
Common Stock
7590
0
I
See footnotes
780,980 shares of Series C Convertible Preferred Stock converted to 780,980 shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
The securities are held of record by Hatteras Venture Partners III, L.P. ("HVPIII") and Hatteras Venture Affiliates, L.P. ("HVAIII"). Hatteras Venture Advisors, LLC is the General Partner of HVPIIII. The reporting person, a partner in HVPIII and HVAIII, has voting and investment power over the shares beneficially owned by HVPIII and HVAIII, and disclaims beneficial ownership of the shares beneficially owned by HVPIII and HVAIII, except to the extent of his pecuniary interest therein.
/s/ Richard L. Sherman, Attorney-In-Fact for Douglas Reed
2013-12-19